Synthetic Drug Crisis Outpaces Payer Playbooks: What SUD Operators Must Do Now
Xylazine, nitazenes, tianeptine, and synthetic benzos are reshaping detox length of stay and acuity, but commercial payer grids and Medicaid MCOs have not caught up. AHS shows operators how to defend medical necessity, win single-case agreements, and stop the denial bleed.









